- For Print
- March 8, 2018
Listed Company Name: Eisai Co., Ltd.
Representative: Haruo Naito
Officer and CEO
Securities Code: 4523
Stock Exchange Listings: First Section of the Tokyo
Inquiries: Masatomi Akana
Vice President, Corporate Affairs
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “the Company”) announced today that based on the impact of the strategic oncology collaboration for anticancer agent Lenvima announced today as well as recent trends in business results, etc., the Company has revised its consolidated financial forecasts for the fiscal year ending March 31, 2018 (April 1, 2017 to March 31, 2018) previously announced on May 10, 2017, as follows.
1. Revised consolidated financial forecasts for the fiscal year ending March 31, 2018 (April 1, 2017 to March 31, 2018)
(Unit: Millions of yen, unless otherwise noted.)
*You can scroll to the left or right here
to owners of
|Previously announced forecast (A)
(May 10, 2017)
|Currently revised forecast (B)||598,000||82,000||81,200||57,600||55,000||192.22 yen|
|Change in amount (B - A)||22,500||22,000||22,900||16,300||15,200|
|Percentage of change (%)||3.9%||36.7%||39.3%||39.5%||38.2%|
|(Reference) Business results for the fiscal year ended March 31, 2017||539,097||59,064||57,668||42,246||39,358||137.63 yen|
2. Reason for revision of the consolidated financial forecasts
Due to the recording of contractual upfront payment (¥32,000 million), etc. based on the strategic oncology collaboration for anticancer agent Lenvima, in addition to recent trends in business results, etc., revenue is expected to increase by ¥22,500 million from the previous forecast to ¥598,000 million (up 10.9% year on year) and operating profit is expected to increase from the previous forecast by ¥22,000 million to ¥82,000 million (up 38.8% year on year). Profit for the period attributable to owners of the parent is expected to increase by ¥15,200 million from the previous forecast to ¥55,000 million (up 39.7% year on year). The Company intends to set the dividend for the period (second six-month period ending March 31, 2018) at ¥80 per share, with the forecast for the total dividend for the year remaining unchanged at ¥150 per share (same amount as the previous fiscal year).
Furthermore, the accounting administration for the recording of one-time payments based on the execution of the strategic oncology collaboration is currently being confirmed with the Company’s accounting auditor.
*Please note that actual business results may change due to several factors since the above-mentioned forecasts were made based on information available as of March 8, 2018.